Compare DigitalOcean Holdings Inc (DOCN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? DigitalOcean Holdings Inc trades at $134.82 (market cap $14.57B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: DigitalOcean Holdings Inc is far larger — about 6.8× Recursion Pharmaceuticals Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DOCN | RXRX | |
|---|---|---|
Market Cap | $14.57B | $2.14B |
Volume | 2,261,786 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $181.29 | $6.79 |
52-Week Low | $37.30 | $2.84 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $15.33B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $134.82, up 5.92% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with RSI levels in oversold territory, while fundamentals reveal impressive revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive at $259M. Recent announcements include new AI-focused Agent Droplets and a $725M equipment financing facility to support capacity expansion.
DOCN presents growth potential with strong analyst support (68% buy ratings) and a $172.73 consensus price target, though elevated valuation ratios (P/E 56.32, P/S 13.96) and negative shareholder equity pose risks. The company's AI-native cloud strategy shows promise, but execution risks and competitive pressures in the cloud infrastructure space require monitoring.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
